The mutant peptide arising as a consequence of TP53 R248Q mutation could bind to HLA-C07:02 and be presented as a potential neoantigen in four patients, which is the most frequent neoantigen in bladder cancer. Here, TP53 is linked to urinary bladder carcinoma.